NKNadezhda Kryukova

Nadezhda Kryukova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadezhda Kryukova has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Birt - Hogg - Dube syndrome: a case series

    by Yu. L. Melyanovskaya, E. I. Kondratyeva, V. I. Elagina, D. S. Mikhaylenko, N. O. Kryukova, V. D. Zolotnitsyna, V. V. Danilov, D. G. Soldatov

    Familial spontaneous pneumothorax (SP) is a rare genetic lung disorder characterized by unilateral or bilateral accumulation of air in the pleural space in patients with a positive family history and no underlying lung disease or prior chest trauma. One of the most common causes of SP is Birt - Hogg - Dubd syndrome (BHDS). The aim of this study was to demonstrate clinical cases of spontaneous pneumothorax caused by genetic variants in the FLCN gene and the need for DNA testing. Results. We presented three clinical cases of patients of different genders, ages, and medical histories who contacted our tertiary center to confirm the diagnosis. All patients had no evidence of altered alpha-1 antitrypsin levels, and their radiographic findings revealed pneumothorax. Despite the wide variety of clinical presentations among patients and their relatives, the diagnosis of BHDS was suspected and the pathogenic variant in the FLCN gene was subsequently confirmed in all of them. Two patients underwent surgery for pneumothorax. One patient was diagnosed with kidney cancer, one had fibrofolliculoma-like skin lesions. All patients were recommended dynamic follow-up, and their relatives were recommended further examination. Conclusion. Since pneumothorax may be the first symptom of a complex multisystem genetic disease, specialists of various specialties should be aware of this disorder at all stages of medical care.

  • Open Access

    Pulmonary Arteriovenous Malformation in a 43-Year-Old Male Patient

    by М. V. Samsonova, P. А. Nikitin, А. L. Chernyaev, М. А. Mikushina, V. V. Danilov, Z. R. Omarova, N. О. Kryukova, А. М. Bostanova

    Pulmonary arteriovenous malformation (PAVM) is an embryonic disorder of pulmonary vessels characterized by a communication between arterial and venous vessels. It occurs in 2–3 cases per 100 thousand population. In 60–70% of cases, PAVM can be single, in 30–40% of cases they are multiple, in 75% of cases – unilateral. It is known that the effect of oncogenes, teratogens, and ionizing radiation in the 7–12th weeks of embryogenesis is a prerequisite for the formation of vascular anomalies. However, the main role belongs to genetic factors involved in angiogenesis, inflammatory cytokine genes and genes encoding factors involved in vascular wall remodeling. The article presents a clinical case of PAVM in S4, S5 of the left lung diagnosed by contrast-enhanced multislice computed tomography. The pathology was detected in a 43-year-old male patient who complained of non-productive cough, inspiratory dyspnea with minor physical exertion, headaches, severe general weakness, which appeared after left-sided pneumonia suffered a month before admission to the hospital. Left-sided video-assisted thoracic surgery was performed with segmentectomy of S4, S5 left lung segments. Histological examination revealed arteriovenous anastomoses.

  • Dirofilariasis as a cause of focal and pathological lung lesions

    by O. N. Brodskaya, M. Krichen, N. O. Kryukova, V. V. Danilov, A. L. Cherniaev, M. V. Samsonova, A. A. Ilin, M. S. Shidakov, S. D. Gorbunkov

    The incidence of dirofilariasis in humans is increasing worldwide. Dirofilariasis is the only mosquito-borne transmissible helminthiasis recorded in the Russian Federation. The definitive hosts of this helminth are dogs, cats, and wild predators; humans are rarely infected. The most common infections in humans and animals are caused by Dirofilaria repens and Dirofilaria immitis . The main sites of dirofilaria infestation in humans are the subcutaneous tissue, periorbital area, and lungs. Pulmonary dirofilariasis is usually asymptomatic, detected as a focal or pathological lesion on chest X-ray. Currently, noninvasive laboratory diagnostic methods for dirofilariasis are lacking; diagnosis is established by histological examination of lung tissue. Treatment of the disease is usually surgical. The aim of the work was to demonstrate and discuss in detail the epidemiology, clinical picture, approaches to diagnosis and treatment of two clinical observations of the classic low-symptom course of pulmonary dirofilariasis. Surgical intervention was necessary to exclude a malignant lung tumor. The epidemiological features, clinical, radiological, and pathological presentation of the disease, complications, and patient management are discussed. Conclusion. Pulmonary dirofilariasis should be considered in the differential diagnosis of focal and pathological lung lesions. Improvement of noninvasive laboratory methods for detecting this helminthiasis in humans is necessary.

  • Open Access

    Phagocytic activity of blood monocytes and neutrophils in moderate COVID-19 patients and impact of immune therapy with bacterial lysates

    by Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Viliya Gajnitdinova, Irina Bisheva, Svetlana Skhodova, Valerij Osiptsov, Vitalij Tatevosov, Nadezhda Kryukova, Isabella Khrapunova, et al.

    Background: Monocytes, macrophages and dendritic cells are involved in phagocytic reactions, which potentially play an important role in the pathogenesis of COVID-19. Imbalance of these cells in peripheral blood has proven to affect not only innate but also adaptive immunity. It is possible that a search for strategies to restore monocyte activity could be a major step in achieving immune control over COVID-19. The aim of this study was to investigate the relationship between phagocytic activity of peripheral-blood monocytes and neutrophils, and COVID-19 severity, to assess the effects of a bacteria-based immunostimulating agent on phagocytosis parameters in in-hospital COVID-19 patients. Materials and methods: The study included 105 adult patients with moderate COVID-19, who had been hospitalized in 2020–2021 and treated in accordance with the recommendations of the Ministry of Health of the Russian Federation. All patients were divided into two groups: in Group 1 patients received standard treatment and Immunovac VP4 therapeutic vaccine, a bacteria-based immunostimulating agent as add-on therapy from Day 1 of hospitalization; in Group 2 patients did not receive any add-on treatment. The study parameters included C-reactive protein (CRP), aspartate aminotransferase (AST), SpO2, lung involvement on chest computer tomography (CT) scan, and phagocytic activity of peripheral-blood leukocytes based on the absorption activity (AA) of monocytes and neutrophilic granulocytes against S. аureus). The parameters were assessed at 1, 14 and 30 days. Results: Based on a cluster analysis of the clinical findings and the results of diagnostic tests obtained on admission, the patients were divided into 2 clusters: cluster 1 including patients with a more severe disease (n = 34) and cluster 2 including patients with a less severe disease (n = 71). Cluster 1 patients had higher levels of CRP (20.1 vs. 2.2 mg/mL, p < 0.001), AST (32.9 vs. 26.2 U/L, p = 0.003), lower SpO2 (94% vs. 96%, p < 0,001) and more extensive lung involvement on chest CT scan (35% vs. 12%, p < 0,001). There was a statistically significant direct correlation between blood monocyte AA and SpO2 (p = 0.04), an inverse correlation between monocyte AA and CRP (p = 0.003) and the extent of lung involvement on CT scan (p = 0.05). In less severe COVID-19 patients (cluster 2), no statistically significant correlation was observed. In more severe COVID-19 patients (cluster 1), there was a rise in monocyte AA on day 30 of hospitalization both in the control group (from 86.6 to 92.2, p = 0.03) and the main group, who received Immunovac VP4 add-on therapy (from 87.3 to 98.3, p = 0.05). However, the patients who received the immunostimulating agent, had higher monocyte PI than the controls, without the immunostimulant (p = 0.05). Patients from cluster 1 who were given Immunovac VP4 had higher SpO2 levels (98% vs. 97%, p = 0.01) than those who had received only the standard treatment. Discussion: Blood monocyte AA correlates with COVID-19 severity: patients with less severe disease have higher AA and those with more severe illness have lower AA. The standard treatment, combined with Immunovac VP4 enhances phagocytic activity of peripheral-blood monocytes, which is associated with a more marked increase in SpO2, especially in more severe patients.


  • Open Access

    Clinical status and cytokine profiles in patients with asthma or chronic obstructive pulmonary disease vaccinated against influenza

    by Mikhail Kostinov, Alexander Chuchalin, Anna Chebykina, Isabella Khrapunova, Alexander Cherdantsev, Irina Solov’eVa, Nelli Akhmatova, Valentina Polishchuk, Nadezhda Kryukova, Aristitsa Kostinova, et al.

    Background: Influenza vaccine is a tool for preventing infection and reducing exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). However, the associations between clinical outcomes and changes in the levels of inflammation markers have not been fully delineated. The purpose of this study was to investigate the clinical course and the changes in the levels of inflammation markers in patients with asthma or chronic obstructive pulmonary disease for one year after vaccination against influenza. Methods: The prospective study for one year included 34 patients with asthma, 20 patients with COPD vaccinated against influenza, both groups being under a basic maintenance therapy, and 26 healthy individuals vaccinated with the trivalent polymer-subunit (adjuvanted) vaccine, containing 5 μg of influenza virus strains and 500 μg of azoximer bromide. The levels of C-reactive protein (CRP) and serum cytokines (IL-2, IL-6, IL-10, and IL-17) were measured by enzyme-linked immunosorbent assay (ELISA) at baseline and 6 and 12 months after vaccination. Results: Over a year after vaccination against influenza, the frequency and duration of bronchopulmonary exacerbations significantly decreased both in patients with asthma and those with COPD: by 1.9–2 and 2.2–2.5 times, respectively. There was also a significant reduction in the frequency and duration of hospitalization (by 2.0–2.5 and 2.3–3 times, respectively). Other changes observed over the one-year follow-up period included a 1.6-fold reduction (р<0.01) in the need for outpatient care and a reduction in the number of courses of systemic corticosteroids (by 16.7%; р<0.05) in asthma patients; and a 3.6-fold decrease (р<0.05) in the number of courses of antibiotics in COPD patients. Twelve months after vaccination against influenza, the study participants had significantly lower IL-6 levels, and COPD patients, additionally, showed a reduction in IL-10 levels compared to baseline. Our study identified certain correlations between positive clinical outcomes of vaccination and levels of inflammation markers. Discussion: Analysis of the immunological, clinical and functional parameters in asthma and COPD patients showed that vaccination not only reduces the risk of influenza and other respiratory infections due to activation of non-specific protection, but also improves the clinical course of asthma and COPD.